Aelis Farma SA AELIS
EURONEXT · France · Health Technology
€0.8700-0.03 (-3.33%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
BORDEAUX, France, September 24, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces that its 2026 half-year financial report has been made available to the public and filed with the French Financial Markets Authority (Autorité des marchés financiers).
The global cannabis use disorder market is projected to grow significantly from 2025 to 2035, driven by cannabis legalization, rising awareness, research funding and demand for effective addiction treatments. Investigational therapies include cannabinoid receptor modulators and serotonin-based drugs, such as Aelis Farma’s AEF0117 and Anebulo Pharmaceuticals’ ANEB-001. North America is expected to lead, followed by Europe, while Asia-Pacific and other regions offer emerging opportunities. Key bar
BORDEAUX, France, September 15, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor of the endocannabinoid system, today announces its financial results for the first half of 2026 and provides an update on its progress and development outlook.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.